Page 52 - Read Online

Page 14 of 16 Iruzubieta et al. Metab Target Organ Damage. 2025;5:10 https://dx.doi.org/10.20517/mtod.2024.143

REFERENCES
1. Addison T. Observations on fatty degeneration of the liver. Guys Hosp Rep. 1836;1:476-85. Available from https://catalog.hathitrust.
org/Record/010088303 [Last accessed on 5 Mar 2025].
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc. 1980;55:434-8. PubMed
3. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease
(NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47. DOI PubMed PMC
4. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-64. DOI PubMed
5. Genua I, Iruzubieta P, Rodríguez-Duque JC, Pérez A, Crespo J. NAFLD and type 2 diabetes: a practical guide for the joint
management. Gastroenterol Hepatol. 2023;46:815-25. DOI PubMed
6. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic
associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1. DOI PubMed
7. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56. DOI PubMed
8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-
analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. DOI PubMed
9. Hong S, Sun L, Hao Y, et al. From NAFLD to MASLD: when metabolic comorbidity matters. Ann Hepatol. 2024;29:101281. DOI
PubMed
10. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-
steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148-55. DOI PubMed
11. Shang Y, Grip ET, Modica A, et al. Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes.
Diabetes Care. 2024;47:978-85. DOI PubMed PMC
12. Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in
United States adults. Liver Int. 2024;44:1051-60. DOI PubMed
13. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of
cardiovascular disease. Cardiovasc Diabetol. 2018;17:122. DOI PubMed PMC
14. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol.
2010;25:375-84. DOI PubMed
®
15. Lombardi R, Airaghi L, Targher G, et al. Liver fibrosis by FibroScan independently of established cardiovascular risk parameters
associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver Int. 2020;40:347-54. DOI
PubMed
16. Li G, Peng Y, Chen Z, Li H, Liu D, Ye X. Bidirectional association between hypertension and NAFLD: a systematic review and meta-
analysis of observational studies. Int J Endocrinol. 2022;2022:8463640. DOI PubMed PMC
17. Siddiqui MS, Fuchs M, Idowu MO, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with
atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13:1000-8.e3. DOI PubMed PMC
18. Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of
cardiovascular risk--a review of the literature. Eur J Clin Nutr. 2010;64:16-22. DOI PubMed
19. De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better
than MAFLD criteria for lean patients with NAFLD. J Hepatol. 2024;80:e61-2. DOI PubMed
20. Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease
(MASLD): beyond insulin resistance. J Hepatol. 2023;79:1524-41. DOI PubMed
21. Duseja A, De A, Wong V. Special population: lean nonalcoholic fatty liver disease. Clin Liver Dis. 2023;27:451-69. DOI PubMed
22. Alboraie M, Butt AS, Piscoya A, et al. Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in
metabolic dysfunction-associated liver diseases. Med Sci Monit. 2024;30:e945198. DOI PubMed PMC
23. Park H, Yoon EL, Kim M, Cho S, Nah EH, Jun DW. Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD):
considerable proportions of MAFLD are metabolic healthy. Clin Gastroenterol Hepatol. 2023;21:1041-9.e3. DOI PubMed
24. Huang J, Kumar R, Wang M, Zhu Y, Lin S. MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically
relevant? J Hepatol. 2020;73:1265-7. DOI PubMed
25. Meroni M, Longo M, Paolini E, et al. MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. J
Intern Med. 2022;291:374-6. DOI PubMed
26. Sookoian S, Rotman Y, Valenti L. Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update. Clin
Gastroenterol Hepatol. 2024;22:2177-87.e3. DOI PubMed PMC
27. Thakral N, Desalegn H, Diaz LA, et al. A precision medicine guided approach to the utilization of biomarkers in MASLD. Semin Liver
Dis. 2024;44:273-86. DOI PubMed
28. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology.
2005;42:987-1000. DOI PubMed
29. Liebe R, Esposito I, Bock HH, et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74:1455-71.
DOI PubMed
30. Staufer K, Huber-Schönauer U, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in